問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

Division of Others-

更新時間:2023-09-19

陳德鴻
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

13Cases

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2018-08-23 - 2020-07-31

Phase II

A phase II, Multi-Center, Open-Label, Single-Arm Study to evaluate the clinical validity and safety of IOP injection for magnetic resonance imaging (MRI) contrast agent in patients with Hepatocellular Carcinoma (HCC)
  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    IOP injection

Participate Sites
8Sites

Not yet recruiting6Sites

Terminated1Sites

2023-08-01 - 2027-04-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2